<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02020629</url>
  </required_header>
  <id_info>
    <org_study_id>16</org_study_id>
    <secondary_id>2012-004959-36</secondary_id>
    <nct_id>NCT02020629</nct_id>
  </id_info>
  <brief_title>Study on Lixisenatide and Counterregulation to Hypoglycemia</brief_title>
  <official_title>Effect of Lixisenatide on Glucagon Secretion During Hypoglycemia in Patients With Insulin-treated Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In hypoglycemia, there is a counterregulation to restore glucose levels. An important part of&#xD;
      this counterregulation is the release of the hormone glucagon. Since the GLP-1 receptor&#xD;
      agonist lixisenatide has been shown to be associated with a low risk of hypoglycemia, this&#xD;
      study examines whether lixisenatide affects the glucagon response to hypoglycemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a single-center, randomized, placebo-controlled study with a cross-over design&#xD;
      and examines the glucagon response during a hyperinsulinemic hypoglycemic phase after a&#xD;
      6-week treatment with lixisenatide (or placebo) as add-on to basal insulin and metformin. The&#xD;
      hypothesis of the study is that the glucagon counterregulation to hypoglycemia in patients&#xD;
      treated with lixisenatide and basal insulin is not lower than in patients treated with basal&#xD;
      insulin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucagon response to hypoglycemia</measure>
    <time_frame>30 min</time_frame>
    <description>Hypoglycemia is induced by clamp during 30 min; glucagon levels are measured during this time frame</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cortisol response to hypoglycemia</measure>
    <time_frame>30 min</time_frame>
    <description>Hypoglycemia is induced by a clamp during 30 min. Cortisol is measured during this time frame.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Catecholamines</measure>
    <time_frame>30 min</time_frame>
    <description>Hypoglycemia is induced by a clamp during 30 min. Catecholamines are measured during this time frame.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>HbA1c</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in HbA1c during six weeks treatment</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Lixisenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lixisenatide 20µg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lixisenatide</intervention_name>
    <description>Lixisenatide is given for 6 weeks whereafter a hypoglycemia clamp is undertaken</description>
    <arm_group_label>Lixisenatide</arm_group_label>
    <other_name>Lyxumia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male, non-fertile female or female of childbearing potential using a medically&#xD;
             approved birth control method aged &gt;18 years.&#xD;
&#xD;
          2. Adult patients with type 2 diabetes treated with basal insulin (NPH insulin, insulin&#xD;
             detemir, insulin glargine or insulin degludec) (stable insulin dose (±10%) during the&#xD;
             last three months) with concomitant at &gt;3 months stable dose (&gt;1500 mg daily) of&#xD;
             metformin.&#xD;
&#xD;
          3. HbA1c &lt;10% (DCCT standard; &lt; 83 mmol(mol) at visit 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treatment with antihyperglycemic agents apart from basal insulin and metformin, i.e.,&#xD;
             bolus insulin or other antihyperglycemic oral agents apart from metformin&#xD;
&#xD;
          2. Type 1 diabetes (including LADA)&#xD;
&#xD;
          3. Pregnant or lactating female. Women of childbearing potential with no effective&#xD;
             contraceptive method. Acceptable contraceptive include contraceptive sponge; hormonal&#xD;
             contraception pills, patches, vaginal rings, injectable contraceptives; and&#xD;
             intrauterine devices. Women of childbearing potential (pre-menopausal, not surgically&#xD;
             sterile women for at least 3 months prior to the time of screening) must have a&#xD;
             confirmed negative serum pregnancy test at screening visit. They must use an effective&#xD;
             contraceptive method throughout the study, and agree to repeat pregnancy tests at&#xD;
             designated visits. The applied methods of contraception have to meet the criteria for&#xD;
             a highly effective method of birth control according to the &quot;Note for guidance on&#xD;
             non-clinical safety studies for the conduct of human clinical trials for&#xD;
             pharmaceuticals (CPMP/ICH/286/95)&quot;&#xD;
&#xD;
          4. A history of any secondary forms of diabetes, e.g., Cushing's syndrome and acromegaly.&#xD;
&#xD;
          5. Acute infections which may affect blood glucose control within 4 weeks prior to visit&#xD;
             1&#xD;
&#xD;
          6. Any history of recent (&lt;2 weeks) recurrent or severe hypoglycemic episodes or&#xD;
             hypoglycemia unawareness&#xD;
&#xD;
          7. Donation of one unit (500 ml) or more of blood, significant blood loss equaling to at&#xD;
             least one unit of blood within the past 2 weeks or a blood transfusion within the past&#xD;
             8 weeks.&#xD;
&#xD;
          8. Treatment with growth hormone and oral or parenteral corticosteroid (&gt; 7 consecutive&#xD;
             days of treatment) within 8 weeks prior to visit 1 and thereafter during the whole&#xD;
             study period.&#xD;
&#xD;
          9. Use of other investigational drugs within 30 days prior to visit 1.&#xD;
&#xD;
         10. Laboratory findings at the time of screening, including amylase and/or lipase &gt; 3&#xD;
             times the upper limit of the normal laboratory range (ULN) and P-calcitonin ≥20 pg/ml&#xD;
             (5.9 pmol/L).&#xD;
&#xD;
         11. Personal or immediate family history of medullary thyroid cancer (MTC) or genetic&#xD;
             condition that predisposes to MTC (e.g. multiple endocrine neoplasia syndromes).&#xD;
&#xD;
         12. History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy,&#xD;
             stomach/gastric surgery&#xD;
&#xD;
         13. Allergic reaction to any GLP-1 receptor agonist or to metacresol&#xD;
&#xD;
         14. Clinically relevant history of gastrointestinal disease associated with prolonged&#xD;
             nausea and vomiting,&#xD;
&#xD;
         15. Cardiovascular, hepatic, neurological, or endocrine disease, active malignant tumor or&#xD;
             other major systemic disease or patients with short life expectancy making&#xD;
             implementation of the protocol or interpretation of the study results difficult.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Ahrén, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Department</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>December 16, 2013</study_first_submitted>
  <study_first_submitted_qc>December 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2013</study_first_posted>
  <last_update_submitted>December 12, 2015</last_update_submitted>
  <last_update_submitted_qc>December 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lund University</investigator_affiliation>
    <investigator_full_name>Bo Ahren</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Glucagon</keyword>
  <keyword>Hypoglycemia</keyword>
  <keyword>Counterregulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lixisenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

